New hope for 10x’ preliminary injunction after EPO Opposition Division ruling | Patent at issue concerns single-cell spatial ...

Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

Bank of New York Mellon Corp lowered its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 13.5% in the ...

Shares of 10x Genomics, Inc. (NASDAQ:TXG – Get Free Report) have received a consensus rating of “Hold” from the seventeen analysts that are currently covering the company, Ratings reports. One ...

Single-cell transcriptomics has revolutionized the study of cellular diversity and function by enabling gene expression ...

The Bioinformatics Data Center (BDC) provides new high-throughput techniques, e.g. next-generation sequencing (NGS) for clinical and preclinical research as part of Genomic Medicine Sweden (GMS) and ...

Popcorn is one of my all-time favorite snacks, especially now that I have to eat gluten-free. It's a quick way to fill me up without having to worry about what's in it. Whether it's buttery movie ...

2025 shows a bright picture of the digital world with an increase in tokenized lands by 60% to $13.5 billion. US spot bitcoin ETFs continue to see a flood of institutional investors. The market offers ...

This comes on the heels of Parse invalidating the patents that 10x Genomics had asserted against Parse's Evercode Whole Transcriptome products and the subsequent cancellation of a trial on those ...

From AI-driven tools to new applications, Epic continues to help healthcare organizations advance in a rapidly changing environment. VERONA, Wis., March 4, 2025 /PRNewswire/ -- At the 2025 HIMSS ...

Genomics (TXG) provided an update on its patent litigation with Parse Biosciences. Through a consent agreement entered on February 25, in ...